miR‐200c/Bmi1 axis and epithelial–mesenchymal transition contribute to acquired resistance to <scp>BRAF</scp> inhibitor treatment
Shujing Liu(University of Pennsylvania), Xiaowei Xu(University of Pennsylvania), Lynn M. Schuchter(Eastern Cooperative Oncology Group), Lin Xie(Foshan University), Meenhard Herlyn(The Wistar Institute), Giorgos C. Karakousis(Hospital of the University of Pennsylvania), Clemens Krepler(Merck & Co., Inc., Rahway, NJ, USA (United States)), Marilda Beqiri(The Wistar Institute), Min Xiao(Tongji Hospital), Michael T. Tetzlaff(Hospital of the University of Pennsylvania), Gao Zhang(Central South University), Yingjie Wang(Xiamen University), Lin Zhang(Simon Fraser University), Tao Wang, Ruifeng Yang(Chinese Academy of Medical Sciences & Peking Union Medical College), Litao Zhang(Tianjin University of Traditional Chinese Medicine), Wei Xu(Peking University), Weiting Xu(New Jersey Institute of Technology), Zhi Wei(New Jersey Institute of Technology), Yuan Yao(University of Toronto), Ravi K. Amaravadi(University of Pennsylvania)
Cited by 53
Related Papers
Host–microbe interactions have shaped the genetic architecture of inflammatory bowel disease
|Nature|2012|4.8k
Guidelines for the use and interpretation of assays for monitoring autophagy
|Autophagy|2012|4.1k
Analysis of shared heritability in common disorders of the brain
|Science|2018|2k
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
|Nature|2010|1.8k
Autophagy in major human diseases
|The EMBO Journal|2021|1.6k